Why Ensign Group (ENSG) is a Top Value Stock for the Long-Term

In this article:

Taking full advantage of the stock market and investing with confidence are common goals for new and old investors alike.

While you may have an investing style you rely on, finding great stocks is made easier with the Zacks Style Scores. These are complementary indicators that rate stocks based on value, growth, and/or momentum characteristics.

Why Investors Should Pay Attention to This Value Stock

Finding good stocks at good prices, and discovering which companies are trading under their true value, are what value investors like to focus on. So, the Value Style Score takes into account ratios like P/E, PEG, Price/Sales, and Price/Cash Flow to highlight the most attractive and discounted stocks.

Ensign Group (ENSG)

Founded in 1999 and headquartered in San Juan Capistrano, CA, The Ensign Group Inc. provides health care services in the post-acute care continuum, urgent care center and mobile ancillary businesses in the United States.

ENSG boasts a Value Style Score of A and VGM Score of A, and holds a Zacks Rank #2 (Buy) rating. Shares of Ensign Group are trading at a forward earnings multiple of 19.7X, as well as a PEG Ratio of 1.3, a Price/Cash Flow ratio of 17.8X, and a Price/Sales ratio of 1.6X.

A company's earnings performance is important for value investors as well. For fiscal 2023, four analysts revised their earnings estimate higher in the last 60 days for ENSG, while the Zacks Consensus Estimate has increased $0.02 to $4.70 per share. ENSG also holds an average earnings surprise of 0.5%.

Investors should take the time to consider ENSG for their portfolios due to its solid Zacks Ranks, notable earnings and valuation metrics, and impressive Value and VGM Style Scores.

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

The Ensign Group, Inc. (ENSG) : Free Stock Analysis Report

To read this article on Zacks.com click here.

Zacks Investment Research

Advertisement